Short Interest in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Expands By 23.3%

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) saw a significant increase in short interest in January. As of January 30th, there was short interest totaling 6,208,105 shares, an increase of 23.3% from the January 15th total of 5,033,852 shares. Based on an average daily trading volume, of 1,236,585 shares, the short-interest ratio is presently 5.0 days. Currently, 6.7% of the company’s stock are short sold. Currently, 6.7% of the company’s stock are short sold. Based on an average daily trading volume, of 1,236,585 shares, the short-interest ratio is presently 5.0 days.

Analysts Set New Price Targets

A number of research analysts recently weighed in on CMPS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of COMPASS Pathways in a research note on Wednesday, January 21st. Royal Bank Of Canada increased their price target on COMPASS Pathways from $16.00 to $21.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Compass Point set a $15.00 price objective on shares of COMPASS Pathways in a research note on Thursday, February 12th. Morgan Stanley upped their price objective on shares of COMPASS Pathways from $10.00 to $11.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Finally, Lifesci Capital upgraded shares of COMPASS Pathways to a “strong-buy” rating in a report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, COMPASS Pathways presently has a consensus rating of “Moderate Buy” and an average price target of $16.11.

COMPASS Pathways Trading Up 31.3%

Shares of CMPS stock opened at $7.63 on Wednesday. The firm has a market capitalization of $732.63 million, a P/E ratio of -2.81 and a beta of 1.92. COMPASS Pathways has a 1 year low of $2.25 and a 1 year high of $8.80. The firm’s fifty day simple moving average is $6.77 and its 200 day simple moving average is $5.89. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 0.55.

More COMPASS Pathways News

Here are the key news stories impacting COMPASS Pathways this week:

• Positive Sentiment: COMP360 met the primary endpoint in a late‑stage (Phase 3) study, driving optimism about regulatory and commercial prospects for the psilocybin therapy. This is the main catalyst for the rally. Compass Pathways’ depression treatment meets main goal in late‑stage study
• Positive Sentiment: Compass announced it will report new clinical data from two ongoing Phase 3 trials (COMP005 and COMP006) and provided a timeline for additional Phase 3 results, reinforcing near‑term news flow that supports further upside. Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
• Positive Sentiment: Market activity shows heightened bullish positioning: unusually large call option volume (over 10,000 calls) and extremely heavy equity volume suggest speculative and institutional buying around the trial news, which amplified the stock move. (Internal trading/activity reports)
• Neutral Sentiment: Public and media coverage (Investing.com, PharmaLetter, MSN) amplified investor attention; press coverage supports momentum but doesn’t guarantee regulatory approval or commercial success. Compass Pathways stock soars after positive Phase 3 trial results
• Neutral Sentiment: Reported short‑interest data in the filings appears erroneous (0 shares / NaN changes) and is unreliable as an indicator of bearish positioning or squeeze potential at present.
• Neutral Sentiment: Third‑party analyst commentary and forecasts (e.g., Lifesci Capital coverage) exist but are secondary to the actual trial readouts for near‑term price action. What is Lifesci Capital’s Forecast for CMPS FY2025 Earnings?
• Negative Sentiment: Compass launched a proposed $150M public offering of ADSs (and pre‑funded warrants), which can dilute existing shareholders and may cap near‑term upside despite the positive data. Investors should weigh dilution risk against trial progress. Compass Pathways Launches Proposed $150.0 Million Public Offering

Hedge Funds Weigh In On COMPASS Pathways

Several institutional investors and hedge funds have recently added to or reduced their stakes in CMPS. Persistent Asset Partners Ltd acquired a new position in COMPASS Pathways in the 4th quarter valued at approximately $38,000. Advisory Services Network LLC bought a new stake in shares of COMPASS Pathways during the third quarter valued at approximately $41,000. China Universal Asset Management Co. Ltd. raised its stake in shares of COMPASS Pathways by 46.7% in the second quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company’s stock valued at $51,000 after purchasing an additional 5,817 shares in the last quarter. BIT Capital GmbH bought a new position in COMPASS Pathways in the third quarter worth $54,000. Finally, Conservest Capital Advisors Inc. lifted its position in COMPASS Pathways by 32.5% in the second quarter. Conservest Capital Advisors Inc. now owns 20,363 shares of the company’s stock worth $57,000 after purchasing an additional 5,000 shares during the period. 46.19% of the stock is currently owned by institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.